双極性障害治療薬の世界市場2015-2019

◆英語タイトル:Global Bipolar Disorder Therapeutics Market 2015-2019
◆商品コード:IRTNTR7311
◆発行会社(調査会社):Technavio
◆発行日:2015年12月16日
◆ページ数:94
◆レポート言語:英語
◆レポート形式:pdf
◆納品方法:Eメール
◆調査対象地域:世界
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、双極性障害治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、双極性障害治療薬の世界市場規模及び予測、製品別分析、作用機序別分析、市場シェア、地域別分析/市場規模、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

Bipolar disorder is a psychological disorder characterized by intermittent mood swings. The individual suffering with this disorder experiences extreme poles of either mania or depression or both. The disorder severely affects the personal, social, and professional life of an individual. The symptoms usually include drastic changes in mood, either as a manic episode or a depressive episode. There is no complete cure for the disorder. Atypical antipsychotics, mood stabilizers, and antidepressants are being widely used in for treatment. It is considered as a lifelong disease and the discontinuation of the medication can lead to relapse of the condition.

Technavio’s analysts forecast the global bipolar disorder therapeutics market to grow at a CAGR of 2.24% over the period 2014-2019.

[Covered in this report]
The report covers the present scenario and growth prospects of the global bipolar disorder therapeutics market for 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of bipolar disorder.

Technavio’s report, Global Bipolar Disorder Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, APAC, and EMEA; it also covers the landscape of the global bipolar disorder therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

[Key regions]
• Americas
• APAC
• EMEA

[Key vendors]
• Allergan
• AstraZeneca
• BMS
• Eli Lilly
• GlaxoSmithKline
• Janssen Pharmaceuticals

[Other prominent vendors]
• AbbVie
• Abital Pharma
• Astellas
• Convergence Pharmaceuticals
• D Pharm
• Delpor
• Gedeon Richter
• H. Lundbeck
• Intra-Cellular Therapies
• Novartis
• Noven Pharmaceuticals
• Omeros Corporation
• Otsuka
• Pfizer
• PNBDevCo
• Reviva Pharmaceuticals
• SK Biopharmaceuticals
• Sunovion Pharmaceutical

[Market Driver]
• Increase in prevalence of bipolar disorder
• For a full, detailed list, view our report

[Market challenge]
• Use of alternative therapies
• For a full, detailed list, view our report

[Market trend]
• Rise in public awareness
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding the disorder
• Types of bipolar disorder
• Causes
• Signs and symptoms
• Management
• Self-help
• Epidemiology

PART 06: Pipeline analysis
• ITI-007
• FK949E
• PROCYCLOX
• RP5603
• CNV1061436
• LY2979165
• DP-VPA
• SKL-PSY
• PGW-5
• DLP-114
• DLP-115
• Small molecule targeting GPR78

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation by drug class
• Mood stabilizers
• Anticonvulsants
• Atypical antipsychotics
• Antidepressant drugs
• Anti-anxiety drugs

PART 09: Market segmentation by mechanism of action
• Selective serotonin reuptake inhibitors
• Serotonin-norepinephrine reuptake inhibitors
• Tricyclic antidepressants
• Monoamine oxidase inhibitors
• Benzodiazepines
• Beta blockers
• Others

PART 10: Geographical segmentation
• Global bipolar disorder therapeutics market by geographical segmentation 2014-2019
• Bipolar disorder therapeutics market in Americas
• Bipolar disorder therapeutics market in EMEA
• Bipolar disorder therapeutics market in APAC

PART 11: Market drivers
• Increase in prevalence of bipolar disorder
• High unmet need
• Increase in R&D

PART 12: Impact of drivers

PART 13: Market challenges
• Use of alternative therapies
• Lack of availability of standard diagnostic methods
• Limited awareness of disease
• Increase in patent expiries

PART 14: Impact of drivers and challenges

PART 15: Market trends
• Rise in public awareness
• Patient assistance programs
• Strategic alliances

PART 16: Vendor landscape
• Competitive scenario
• Market share analysis 2014
• Other prominent vendors

PART 17: Key vendor analysis
• Allergan
• AstraZeneca
• BMS
• Eli Lilly
• GSK
• Janssen Pharmaceuticals

PART 18: Appendix
• List of abbreviatios

PART 19: Explore Technavio

Exhibit 01: Product offerings
Exhibit 02: Signs and symptoms of bipolar disorder
Exhibit 03: Signs and symptoms of mania
Exhibit 04: Signs and symptoms of depression
Exhibit 05: Treatment options for bipolar disorder
Exhibit 06: Medications for treating bipolar disorder
Exhibit 07: Global bipolar disorder therapeutics market: Pipeline portfolio
Exhibit 08: Global bipolar disorder therapeutics market 2014-2019 ($ millions)
Exhibit 09: Five forces analysis
Exhibit 10: Segmentation of global bipolar disorder therapeutics market by drug class
Exhibit 11: Global bipolar disorder therapeutics market segment by geography 2014
Exhibit 12: Bipolar disorder therapeutics market revenue by geography 2014-2014 ($ millions)
Exhibit 13: Bipolar disorder therapeutics market in Americas 2014-2019 ($ millions)
Exhibit 14: Bipolar disorder therapeutics market in EMEA 2014-2019 ($ millions)
Exhibit 15: Bipolar disorder therapeutics market in APAC 2014-2019 ($ millions)
Exhibit 16: Impact of drivers
Exhibit 11: Common disorders that co-exist with bipolar disorder
Exhibit 17: Impact of drivers and challenges
Exhibit 18: Market share analysis of global bipolar disorder therapeutics market 2014
Exhibit 19: YoY growth rate of major bipolar disorder drugs 2014-2019 ($ millions)
Exhibit 20: Bristol-Myers Squibb: YoY growth and revenue generated from net product sales of Abilify 2011-2014 ($ millions)
Exhibit 21: Bristol-Myers Squibb: Percentage share of Abilify in US and non-US region based on revenue 2014
Exhibit 22: Bristol-Myers Squibb: Key takeaways
Exhibit 23: AstraZeneca: YoY growth and revenue generated from net product sales of Seroquel XR 2011-2014 ($ millions)
Exhibit 24: AstraZeneca: Revenue generated from sales of Seroquel XR by region 2014 ($ millions)
Exhibit 25: AstraZeneca: YoY growth and revenue generated from net product sales of Seroquel IR 2011-2014 ($ millions)
Exhibit 26: AstraZeneca: Key takeaways
Exhibit 27: Janssen Pharmaceuticals: YoY growth and revenue generated from net product sales of Risperdal Consta 2011-2014 ($ millions)
Exhibit 28: Janssen Pharmaceuticals: Key takeaways
Exhibit 29: Eli Lilly: YoY growth and revenue generated from net product sales of Zyprexa 2011-2014 ($ millions)
Exhibit 30: Eli Lilly: Key takeaways
Exhibit 31: GlaxoSmithKline: YoY growth and revenue generated from net product sales of Lamictal 2011-2014 ($ millions)
Exhibit 32: GlaxoSmithKline: Revenue generated from sales of Lamictal by region 2014 ($ millions)
Exhibit 33: GlaxoSmithKline: Key takeaways
Exhibit 34: Allergan: Key takeaways
Exhibit 35: Allergan: Business segmentation by product revenue 2014
Exhibit 36: Allergan: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 37: Allergan: Geographical segmentation by revenue 2014
Exhibit 38: AstraZeneca: Business segmentation by revenue 2014
Exhibit 39: AstraZeneca: Business segmentation by revenue 2013 and 2014
Exhibit 40: AstraZeneca: Geographical segmentation by revenue 2014
Exhibit 41: BMS: Segmentation by revenue 2014
Exhibit 42: BMS: Segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 43: BMS: Geographical segmentation by revenue 2014
Exhibit 44: Lilly: Business segmentation by revenue 2014
Exhibit 45: Eli Lilly: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 46: Eli Lilly: Geographical segmentation by revenue 2014
Exhibit 47: GSK: Business segmentation by revenue 2014
Exhibit 48: GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 49: GSK: Geographical segmentation by revenue 2014
Exhibit 50: Janssen Pharmaceuticals: Key therapeutic areas



【掲載企業】

Allergan, AstraZeneca, BMS, Eli Lilly, GSK, Janssen Pharmaceuticals, AbbVie, Abital Pharma, Astellas, Convergence Pharmaceuticals, D Pharm, Delpor, Gedeon Richter, H. Lundbeck, Intra-Cellular Therapies, Novartis, Noven Pharmaceuticals, Omeros Corporation, Otsuka, Pfizer, PNBDevCo, Reviva Pharmaceuticals, SK Biopharmaceuticals, Sunovion Pharmaceutical.

【レポートのキーワード】

双極性障害、双極性障害治療薬、医薬品、製薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[双極性障害治療薬の世界市場2015-2019]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年12月08日現在 219,203 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆